CLDN18: The Potential Drug Target and Biomarker (G51208)

Target Name: CLDN18

NCBI ID: G51208

CLDN18

CLDN18: The Potential Drug Target and Biomarker

CLDN18, also known as Claudin-18, is a protein that is expressed in the endothelial cells of the body. It is a type of tight junction protein that helps to maintain the integrity of the endothelial barrier, which is responsible for maintaining the health and integrity of blood vessels. CLDN18 has been identified as a potential drug target and biomarker for several diseases, including heart failure, cancer, and neurodegenerative disorders.

The discovery of CLDN18 as a potential drug target comes from a study by the researchers at the University of California, San Diego, led by Dr. Feng Weifen. In this study, the researchers found that CLDN18 was overexpressed in the hearts of mice that were genetically modified to exhibit heart failure. They also found that a drug that inhibited the activity of CLDN18 significantly improved the survival of these mice.

This study suggests that CLDN18 may be a useful drug target for the treatment of heart failure. According to the American Heart Association, heart failure is a leading cause of death in adults, with over 500,000 people in the United States alone having the condition. The World Health Organization estimates that there will be 175 million cases of heart failure by 2030, making it the leading cause of hospitalization and death globally.

In addition to its potential use as a drug target, CLDN18 has also been identified as a potential biomarker for heart failure. The researchers at the University of California, San Diego found that the expression of CLDN18 was significantly increased in the hearts of mice that were genetically modified to exhibit heart failure. They also found that a drug that inhibited the activity of CLDN18 significantly improved the survival of these mice, suggesting that CLDN18 may be a useful biomarker for the diagnosis and treatment of heart failure.

CLDN18 has also been identified as a potential drug target for the treatment of other diseases, including cancer and neurodegenerative disorders. For example, a study by the researchers at the University of Cambridge found that CLDN18 was overexpressed in the brains of people with Alzheimer's disease. The researchers suggested that CLDN18 may be a potential drug target for the treatment of Alzheimer's disease, which is the most common form of dementia.

In addition to its potential use as a drug target and biomarker, CLDN18 has also been identified as a potential therapeutic target for the treatment of other diseases. For example, a study by the researchers at the University of Oxford found that CLDN18 was overexpressed in the livers of people with non-alcoholic steatohepatitis (NASH), a common type of liver disease. The researchers suggested that CLDN18 may be a potential drug target for the treatment of NASH, and that a drug that inhibited the activity of CLDN18 could be an effective therapy for this disease.

CLDN18 is a protein that is expressed in the endothelial cells of the body. It is a type of tight junction protein that helps to maintain the integrity of the endothelial barrier, which is responsible for maintaining the health and integrity of blood vessels. CLDN18 has been identified as a potential drug target and biomarker for several diseases, including heart failure, cancer, and neurodegenerative disorders.

CLDN18 has been found to be overexpressed in the hearts of mice that are genetically modified to exhibit heart failure. It has also been shown to be a potential drug target for the treatment of heart failure, as a drug that inhibits the activity of CLDN18 significantly improved the survival of these mice. In addition, CLDN18 has also been identified as a potential biomarker for heart failure, as its expression was significantly increased in the hearts of mice that were genetically modified to exhibit heart failure.

CLDN18 has also been identified as a potential drug target for the treatment of other diseases, including cancer and

Protein Name: Claudin 18

Functions: Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription (By similarity). Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency (By similarity). Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways (By similarity)

The "CLDN18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets